TLSI - NASDAQ

TriSalus Life Sciences, Inc.

TLSI·NASDAQ

$3.29

+3.0%

HealthcareMedical - Devices

TriSalus Life Sciences, Inc., an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company offers the TriNav Infusion System for hepatic arterial infusion of liver tumors; and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. It also develops SD-101, an investigational immunotherapeutic with pressure-enabled drug delivery technology for hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company is based in Westminster, Colorado.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$124.72M

EPS-1.8400

P/E Ratio-1.79

Earnings Date08/11/2026

35.33M

Assets

47%

3Y+61.0%

5Y+335.0%

10Y+335.0%

69.19M

Total Liabilities

39%

3Y+102.0%

5Y+19.0%

10Y+19.0%

-33.86M

Total Equity

31%

3Y+175.0%

5Y-32.0%

10Y-32.0%

TriSalus Life Sciences, Inc. Funding & Solvency Profile

TLSI · NASDAQ

Current Assets

Cash & Cash Equivalents20.44M

Net Receivables6.56M

Inventory3.08M

Other Current Assets0.00

Total Current Assets32 M

Non-Current Assets

Property, Plant & Equipment2.67M

Goodwill & Intangible Assets0.00

Long-Term Investments400.00K

Other Non-Current Assets18.00K

Total Non-Current Assets3 M

Total Assets

35.33M

Financial Health Analysis

Current Ratio

2.80x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Working Capital

21 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

91% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

TriSalus Life Sciences, Inc. Balance Sheet

TLSI • NASDAQ

TriSalus Life Sciences, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	20.4M	8.5M	11.8M	9.4M	30.3M	4.5M
Cash & Short-Term Investments	20.4M	8.5M	11.8M	9.4M	30.3M	4.5M
Net Receivables	6.6M	5.1M	3.6M	1.6M	1.4M	617K
Accounts Receivables	6.6M	5.1M	3.6M	1.6M	1.4M	617K
Inventory	3.1M	4M	2.5M	1.5M	1.3M	567K
Prepaids	2.2M	3M	3M	4.8M	2.2M	0.0
Other Current Assets	0.0	0.0	0.0	0.0	0.0	406K
Total Current Assets	32.2M	20.7M	20.9M	17.2M	35.1M	6.1M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	2.7M	2.9M	3.3M	3.6M	1.8M	1.3M
Intangible Assets	0.0	0.0	0.0	802K	794K	736K
Goodwill & Intangible Assets	0.0	0.0	0.0	802K	794K	736K
Long-Term Investments	400K	350K	0.0	250K	0.0	0.0
Other Non-Current Assets	18K	73K	466K	117K	115K	50K
Total Non-Current Assets	3.1M	3.3M	3.7M	4.8M	2.7M	2.1M
Total Assets	35.3M	24M	24.6M	22M	37.8M	8.1M
LIABILITIES
CURRENT LIABILITIES
Total Payables	3.1M	2.3M	3.4M	4.9M	1.3M	612K
Accounts Payable	3M	2.3M	3.4M	4.9M	1.3M	612K
Other Payables	100K	34K	0.0	0.0	0.0	0.0
Accrued Expenses	0.0	7.3M	10.5M	3.5M	5M	6.7M
Short Term Debt	167K	0.0	0.0	370K	0.0	42.2M
Capital Lease Obligations (Current)	0.0	216K	351K	0.0	0.0	0.0
Tax Payables	0.0	34K	0.0	0.0	0.0	0.0
Other Current Liabilities	8.2M	383K	420K	23.6M	104K	5.2M
Total Current Liabilities	11.5M	10.2M	14.7M	32.4M	6.4M	54.7M
NON-CURRENT LIABILITIES
Long Term Debt	34.3M	22.1M	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	23.4M	16.2M	35.7M	369K	561K	3.5M
Total Non-Current Liabilities	57.7M	39.6M	37M	2M	561K	3.5M
Capital Lease Obligations	0.0	1.5M	1.6M	1.6M	0.0	0.0
Total Liabilities	69.2M	49.9M	51.7M	34.3M	6.9M	58.3M
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	0.0	164M	160.5M	56M
Common Stock	4K	3K	2K	0.0	11K	8K
Additional Paid-In Capital	296.7M	253.7M	222.4M	10M	6.7M	1.4M
Retained Earnings	-330.6M	-279.5M	-249.5M	-186.4M	-136.3M	-107.5M
Total Stockholders' Equity	-33.9M	-25.9M	-27.1M	-12.3M	30.9M	-50.2M
Total Equity	-33.9M	-25.9M	-27.1M	-12.3M	30.9M	-50.2M
SUMMARY
Total Liabilities & Equity	35.3M	24M	24.6M	22M	37.8M	8.1M
Total Investments	400K	350K	0.0	250K	0.0	0.0
Total Debt	34.4M	23.6M	1.6M	2M	0.0	42.2M
Net Debt	14M	15.1M	-10.2M	-7.5M	-30.3M	37.7M
Shares Outstanding	37,975,800	37,975,800	37,975,800	37,975,800	37,975,800	37,975,800

SEC Filings

TLSI - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 14, 2026	May 14, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 12, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 12, 2026	May 12, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 29, 2026	April 24, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 07, 2026	April 01, 2026	2026	View Filing
DEF 14A DEF 14A 2025 N/A	March 31, 2026	December 31, 2025	2025	View Filing
10-K 10-K 2025 FY FY	March 05, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 05, 2026	March 05, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 20, 2026	February 19, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 09, 2026	February 03, 2026	2026	View Filing

Showing 1 to 10 of 141 filings

Related Guides

Blog Categories

Continue your TLSI research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.